Postgame wrap of the ultimate blood pressure megatrial did it score an allhat trick or was it "three strikes and you're out?"

Hypertension

Volumn 53, Issue 4, 2009, Pages 595-597

  Feldman, Ross D ^a   Mcalister, Finlay A ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AVALIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL PLUS HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS QUINAPRIL; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; LOSARTAN; PERINDOPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; EDITORIAL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SYSTOLIC HYPERTENSION; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; INFORMATION DISSEMINATION; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 64849087389     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.126169     Document Type: Editorial

References (11)

1. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991:265:3255-3264.
2. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-conrverting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypeitensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA. 2002;288:2981-2997.
3. Muntner P, Krousel-Wood M, Hyre AD, Stanley E, Cushman WC, Cutler JA, Piller LB, Goforth GA, Whelton PK. Antihypertensive prescriptions for newly treated patients before and after the main Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial results and seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure guidelines. Hypertension. 2009;53: 617-623.
4. Chobanian AV, Bakris GL, Black HR, Cushmar WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ, and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42: 1206-1252.
5. Canadian Hypertension Education Program. The 2008 Canadian Hypertension Education Program recommendations: the scientific summary-an annual update. Canadian. Can J Cardiol. 2008;24:447-452.
6. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe- Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE) : a randomised trial against atenolol. Lancet. 2002;359:995-1003.
7. Majumdar SR, McAlister FA, Soumerai SB. Examining the synergy between publication and promotion: a comparison of the adoption of new evidence in Canada and the US. Am J Med. 2003;115:467-472.
8. Campbell NRC, Tu K, Duong-Hua M, Brant R, McAlister FA. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension. 2006;47:22-28.
9. Leenen FH, Dumais J, Mclnnis NH, Turton P, Stratychuk L, Nemeth K, Lum-Kwong MM, Fodor G. Results of the Ontario survey on the prevalence and control of hypertension. CMAJ. 2008;178:1441-1449.
10. Campbell NR, Brant R, Johansen H, Walker RL, Wielgosz A, Onysko J, Gao RN, Sambell C, Phillips S, McAlister FA; for the Canadian Hypertension Education Program Outcomes Research Task Force. Increases in antihypertensive prescriptions and reductions in cardiovascular events in Canada. Hypertension. 2009;53:128-134.
11. Majumdar SR, McAlister FA, Furberg CD. From publication to practice in chronic cardiovascular disease - the long and winding road. J Am Coll Cardiol. 2004;43:1738-1742.